IL-7 Receptor Polymorphisms and Immune Recovery With HAART
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00168207
- Lead Sponsor
- The Alfred
- Brief Summary
The aim is to investigate the hypothesis that IL7-receptor polymorphisms contribute to the differential immune recovery of CD4 + T cells following HAART
- Detailed Description
AIM: To examine the association between the four haplotypes of IL-7Rα gene and a cohort of HIV infected patients who have commenced HAART with varying CD4+ T lymphocyte responses.
METHODS: IL-7Rα gene SNPs and haplotypes will be measured by constructing DNA pools, and PCR amplification and DNA sequencing. IL-7Rα expression will be examined using constitutive expression of IL-7Rα, IL-7Rα gene expression, and inducible expression of IL7Rα.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 106
Inclusion Criteria
- Men or women at least 18 years of age
- First antiretroviral regimen composed of HAART as defined by at least three antiretrovirals
- Controlled viremia for a period of at least 12 months following commencement of HAART. Controlled viremia is defined as HIV viral load of ≤ 500 copies/mL on bDNA testing (versions 2 and 3) and <400 copies/ml measured by RT-PCR assay by 6 months treatment.
- CD4 cell count <500 at commencement of HAART
- Measurement of CD4+ cell count on at least 3 time points, in the 12 months post commencement of HAART.
Exclusion Criteria
- Exclude patients treated for HIV seroconversion illness
- Exclude patients on immunomodulatory therapy such as IL-2, hydroxyurea or prednisolone or who have received an HIV therapeutic vaccine
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
The Alfred Hospital, Commercial Road
🇦🇺Melbourne, Victoria, Australia